Results of combined‐modality therapy for limited‐stage small cell lung carcinoma in the elderlyAdditional participating institutions include the following: Duluth CCOP, Duluth, MN (Daniel A. Nikcevich, M.D.); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA (Martin Wiesenfeld, M.D.); Meritcare Hospital CCOP, Fargo, ND (Ralph Levitt, M.D.); Toledo Community Hospital Oncology Program CCOP, Toledo, OH (Paul L. Schaefer, M.D.); Sioux Community Cancer Consortium, Sioux Falls, SD (Loren K. Tschetter, M.D.); Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair, M.D.); Rapid City Regional Oncology Group, Rapid City, SD (Larry P. Ebbert, M.D.); Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada and Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (Muhammad Salim, M.D.); Scottsdale CCOP, Scottsdale, AZ (Tom R. Fitch, M.D.); Carle Cancer Center CCOP, Urbana, IL (Kendrith M. Rowland, M.D.); Medcenter One Health Systems, Bismarck, ND (Ferdinand Addo, M.D.); Altru Health S

Authors: Steven E. Schild, Philip J. Stella, Burke J. Brooks, Sumithra Mandrekar, James A. Bonner, William L. McGinnis, James A. Mailliard, James E. Krook, Richard L. Deming, Alex A. Adjei, Aminah Jatoi, James R. Jett

Source: Cancer (0008543X); Jun2005, Vol. 103 Issue 11, p2349-2354, 6p

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: Results from Intergroup Trial N9741.

Authors: Thierry Delaunoit, Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Brian P. Findlay, Sachdev P. Thomas, Muhammad Salim, Paul L. Schaefer, Philip J. Stella, Erin Green, James A. Mailliard

Source: Cancer (0008543X); Nov2004, Vol. 101 Issue 10, p2170-2176, 7p

Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients.

Authors: Aminah Jatoi, Shauna Hillman, Philip J. Stella, James A. Mailliard, Jeff Sloan, Stephanie Vanone, Michael W. Cannon, Leila Kutteh, Anne Kanard, James R. Jett

Source: Supportive Care in Cancer; Jul2003, Vol. 11 Issue 7, p460, 5p

Subject Terms: DRUG therapy, CANCER patients, PACLITAXEL

Randomized Phase II Study of Daily Versus Continuous-Infusion Schedules of Topotecan in the Treatment of Extensive-Stage Small Cell Lung Cancers.

Authors: Paul L. Schaefer, Randolph S. Marks, Michelle R. Mahoney, Jeff A. Sloan, Mitchell D. Bauman, Henry D. Tazelaar, John W. Kugler, James A. Mailliard, Larry P. Ebbert, Martin Wiesenfeld

Source: American Journal of Clinical Oncology; Jun2003, Vol. 26 Issue 3, p236-240, 5p

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma.

Authors: James R. Jett, Alan K. Hatfield, Shauna Hillman, Michael D. Bauman, James A. Mailliard, John W. Kugler, Roscoe F. Morton, Randolph S. Marks, Ralph Levitt

Source: Cancer (0008543X); 5/15/2003, Vol. 97 Issue 10, p2498-2503, 6p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non-Small-Cell Lung Cancer.

Authors: Randolph S. Marks, David L. Graham, Jeff A. Sloan, Shauna Hillman, Steven Fishkoff, James E. Krook, Scott H. Okuno, James A. Mailliard, Tom R. Fitch, Ferdinand Addo

Source: American Journal of Clinical Oncology; Aug2003, Vol. 26 Issue 4, p336-337, 2p